Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 13/20 | 0.54 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 2/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 2/20 | 0.36 |
| ▸ | CA9 | Q16790 | 2/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4314856 | 0.89 | CA12 (0.49) | AGTR2CA12CA1CA2CA7 | |
| SCHEMBL27973726 | 0.85 | AGTR2 (0.44) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL1724215 | 0.85 | AGTR2 (0.52) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL4313287 | 0.85 | AGTR2 (0.48) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL4327781 | 0.85 | AGTR2 (0.45) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL4306715 | 0.84 | AGTR2 (0.43) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL4310758 | 0.84 | AGTR2 (0.49) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL27973549 | 0.82 | AGTR2 (0.48) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL27973576 | 0.81 | AGTR2 (0.42) | AGTR2CYP2C9CYP2B6 | |
| SCHEMBL1720597 | 0.76 | AGTR2 (0.86) | AGTR2CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869023-B1 | NEW TRICYCLIC ANGIOTENSIN II AGONISTS | VICORE PHARMA AB (SE) | 2012-01-11 | — | — | EP | disclosed |
| US-8080571-B2 | Tricyclic angiotensin II agonists | VICORE PHARMA AB (SE) | 2011-12-20 | — | — | US | disclosed |
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | VICORE PHARMA AB (SE) | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042931-A1 | Tricyclic Angiotensin II Agonists | AGTR2, AGTR1, NPY4R | AGTR2 1/4885CYP11B1 920/4885CYP11B2 757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.